Amphastar Pharmaceuticals
AMPH
215 hedge funds and large institutions have $634M invested in Amphastar Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 68 increasing their positions, 95 reducing their positions, and 44 closing their positions.
5,570% more call options, than puts
Call options by funds: $1.87M | Put options by funds: $33K
1.8% less ownership
Funds ownership: 73.1% → 71.3% (-1.8%)
9% less funds holding
Funds holding: 235 → 215 (-20)
28% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 95
30% less capital invested
Capital invested by funds: $900M → $634M (-$266M)
32% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$13.2M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$8.62M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.58M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$2.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$10.8M |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$10.3M |
| 3 |
CCMG
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
-$8.5M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$5.73M |
| 5 |
EIP
Epoch Investment Partners
New York
|
-$5.57M |
AMPH Hedge Fund Activity: Q1 2026 in Review
215 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q1 2026, worth a combined $634M — down 30% from $900M a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of AMPH and 30 opened new positions — a net loss of 14 holders — while 95 trimmed existing stakes and 68 added.
The largest buyer was LSV Asset Management, adding an estimated $13.2M. The largest seller was Hotchkis & Wiley Capital Management, exiting entirely with an estimated $10.8M sold.
- 215 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q1 2026, down from 235 in Q4 2025.
- Funds reported $634M of Amphastar Pharmaceuticals stock for Q1 2026, down 30% quarter-over-quarter.
- 30 funds opened new Amphastar Pharmaceuticals positions in Q1 2026 and 44 closed out, a net change of -14 holders.
- The largest Amphastar Pharmaceuticals buyer in Q1 2026 was LSV Asset Management, an estimated $13.2M added.
- The largest Amphastar Pharmaceuticals seller in Q1 2026 was Hotchkis & Wiley Capital Management, an estimated $10.8M sold.
Based on aggregated 13F filings for Q1 2026.